ABSTRACT
Polygenic risk scores (PRSs) provide an individual level estimate of genetic risk for any given disease. Since most PRSs have been derived from genome wide association studies (GWAS) conducted in populations of White European ancestry, their validity in other ancestry groups remains unconfirmed. This is especially relevant for cardiometabolic diseases which are known to disproportionately affect people of non-European ancestry. Thus, we aimed to evaluate the performance of PRSs for glycaemic traits (glycated haemoglobin, type 1, and type 2 diabetes mellitus), cardiometabolic risk factors (body mass index, hypertension, high- and low-density lipoproteins, and total cholesterol and triglycerides) and cardiovascular diseases (CVDs, including stroke and coronary artery disease) in people of White European, South Asian, and African Caribbean ethnicity in the UK Biobank. Whilst the PRSs incorporated some GWAS data from multi-ethnic population, the vast majority originated from White Europeans. Except for hypertension and stroke, PRSs derived mostly from European populations had an overall better performance in White Europeans compared to South Asians and African Caribbeans. Thus, multi-ancestry GWAS data are needed to generate ancestry stratified PRSs to tackle health inequalities.
Competing Interest Statement
The views expressed in this article are those of the authors who declare that they have no conflict of interest except for Nish Chaturvedi who serves on a Data Safety and Monitoring Board for a clinical trial of a glucose lowering agent, funded by AstraZeneca.
Funding Statement
NC received support from the UK Medical Research Council, Diabetes UK, Wellcome Trust, British Heart Foundation and National Institute for Health Research University College London Hospitals Biomedical Research Centre. RM is supported by Barts Charity (MGU0504). VG is funded by the Professor David Matthews Non-Clinical Fellowship (ref: SCA/01/NCF/22). VG is also supported by joint Diabetes UK and British Heart Foundation grant (ref: 15/0005250).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank's ethical approval (11/NW/0382) was from the Northwest Multi-centre Research Committee (MRCEC) in 2011, which was renewed in 2016 and then in 2021. All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Joint last authors
Data Availability
The UK Biobank data is available via an application from https://www.ukbiobank.ac.uk/.
